depakote bipolar dosage
I am the first to see the advantages and virtues of free enterprise model as it applies to sales and drug development. This model encourages pharmaceutical companies to employ people with talent and take risks in developing new drugs for serious medical problems. But let's be honest, current practices also produce unwanted effects.
1. When the drug is suddenly wonderful month is not good.
It was pleasing to the eye of companies pharmaceuticals are suddenly changes in the patentability of drugs when their patents expire old. For example, since the 1970s, Abbott did a dance with target = "_self"> different formulations of valproic acid (used for seizures, migraines and bipolar disorder). As a first step, the brand was Depakene, but when the patent has expired, Depakene suddenly is not good, no more, and Depakote (just different enough to be patentable), was the only drug that we think. Then, when the patent is not Depakote, suddenly it was not good, either. Now, Depakote ER (extended release) is the only way to travel.
This approach to reworking the old long-acting drugs in the formats worked for other pharmaceutical companies as well. For example, GlaxoSmithKline has seen the same dance, with its forms of bupropion for depression, the evolution of the target = "_self"> Wellbutrin Wellbutrin SR (sustained release) for Wellbutrin XL (extended version). Wyeth, see a good thing, followed suit, with an antidepressant venlafaxine, Effexor Effexor XR a (sustained release). It's just a coincidence amazing how the new, suddenly appear better medicines just when the old and the front face of generics.
2. When do we forget that many older drugs.
Since 1954 we have had the effectiveness of anti-psychotic treatment schizophrenia, but in the 1990s a series of new anti-psychotic drugs emerged, now called "atypical" or "new" anti-psychotics. Suddenly, the older drugs – and therefore all affordable generic medicines – not good. Only the new patented anti-psychotics have been good and might even be guilty of professional misconduct if a drug is prescribed more (or set of prescriptions to a patient who seems to be made too). In fact, a new generation of psychiatrists cycling through training programs with this concept in mind, writing is rarely a recipe for an old drug.
The supposed superiority of new drugs has been tested in recent CATIE (Clinical Antipsychotic Trials on the effectiveness of the intervention) to study and be absent. The study compared four new drugs to another drug, perphenazine, and differences in results were minimal to none.
3. By diverting attention drug treatments.
Pharmaceutical companies sell drugs. So when it comes to marketing their products, which have no interest in the promotion – or even mention – the lack of drug treatments. There are vendors making the rounds of doctors' offices to remind physicians rigorously demonstrated the benefits of training in stress management and migraine and tension-type headaches, or cognitive-behavioral depression.
4. When you hook in the samples.
Doctors to receive samples of the patented brand (high-up), and non-patent drugs (low margin) drugs. Therefore, patients are referred to the expensive drugs by using these "loss". "
5. When forms of medical practice.
Pharmaceutical companies aggressively court the leaders believe that as teachers in medical schools, financial incentives, such as the cost of an impressive commitments. Funding is also medical publications. The effects of these marketing activities in practice care are not necessarily beneficial for patients.
For example, tissue plasminogen activator (tPA) is an expensive thrombolytic approved for use in stroke. Its benefits are modest and the risks are real (cerebral hemorrhage and death). Thoughtful physicians could reasonably conclude that the benefits of tPA administration does not outweigh the risks. But this is not the message which comes from the thinking of many leaders and publications. Rather, the implication is that management This drug is a standard of care, which constitutes professional misconduct for failure.
6. When representatives do not promote the use approved.
Recently, a sales representative for Pfizer, said his company drug, pregabalin is effective in preventing migraine. Must have not said that. Pregabalin is approved by the FDA for the treatment of epilepsy and nerve pain, but not migraine. Although doctors in the United States are authorized to prescribe drugs for "off-label uses of drugs, companies are forbidden to advertise their drugs for unapproved uses. In fact, Pfizer has difficulties in pushing other drugs, gabapentin, for unapproved uses.
7. If doctors do not think critically about what they do.
This, strictly speaking, there is a gap in the drug business. But because sellers can see that doctors are expensive, branded drugs, the names of the cheaper (more efficient) alternatives can not come to mind when writing prescriptions. About the Author:
Article Source: ArticlesBase.com – Seven Toxic Effects of Drug Companies
